The aim of Ambiotis is to advance the care of patients suffering from inflammatory disorders.
Ambiotis is a CRO (Contract Research Organization) offering innovative research services and specialized in testing the anti-inflammatory effect of compounds (therapeutic proteins, cosmetics active molecules, probiotics, …) on various models.
More than 50% of our activity is invested in R&D in order to make our business partners satisfied.
The society develops new human cells or functional models-based protocols in order to investigate the inflammatory process involved in:
Created in 2007, Ambiotis is a Young and Innovative Company. The Incubator Midi-Pyrénées was strongly involved in its start-up support.
The company was awarded in 2006-2007 at the National Innovative and Technological Start-Up Competition (organized by the French Ministry of Research) and boosted its growth afterwards.